Fluticasone Propionate Receives NDA but Remains in Short Supply

Fluticasone Propionate Receives NDA but Remains in Short Supply

Fluticasone-Propionate-80474-14-2-FDA-Drug-ShortagesFluticasone Propionate, which is currently short in supply, received a New Drug Application, or NDA at on July 31, 2013. Drug maker Perrigo announced the new drug application for fluticasone propionate lotion, 0.05%. This form of fluticasone propionate lotion is the generic equivalent to Cutivate Lotion, 0.05%. The use of the effectual and tolerable corticosteroid fluticasone propionate as a lotion is extremely helpful for the large population of patients who experience atopic dermatitis. As an effective steroid lotion this newly approved formulation of Fluticasone offers much needed relief  for both pruritic and inflammatory atopic dermatitis. Fluticasone Propionate is already a viable and successful API, found in anti-inflammatory products like the Flovent Inhaler and Advair.

Working to prevent a release of substances in the body which may cause inflammation, Fluticasone Propionate is found in the Flovent Inhaler, which  helps to reduce inflammation in the airways which may be in response to allergens or irritants in the air. This prevention greatly aids patients with asthma, upper respiratory conditions and allergies. Researchers should note that the use of Fluticasone Propionate in children under age four is not approved by the FDA. Children over age four who receive Fluticasone Propionate should be monitored closely as this medication can affect their growth rate. Fluticasone Propionate should not be used in clinical trials to treat any patient who is currently experiencing an acute asthma attack, and rescue inhalers should be on hand for any patients who may encounter this situation.

The adverse effects of Fluticasone Propionate are few, with most patients experiencing mild side effects like a dry mouth, cough, headache, hoarse voice or slight sinus pain. Some patients will experience white patches on the inside of their mouth and lips after taking Fluticasone Propionate, but these effects disappear once treatment has finished.

There is availability of Fluticasone Propionate through LGM Pharma. As a reputable and preferred supplier to the biotech and pharmaceutical industry, LGM Pharma provides the Fluticasone Propionate CAS# 80474-14-2 API, and the Fluticasone Propionate TEVA API, for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service